Bristol-Myers Squibb said on Thursday it would buy Celgene Corp. for about $74 billion, creating a major pharma company with several blockbuster cancer drugs as competition in the immunotherapy space heats up. Bristol-Myers pioneered immunotherapy with its Yervoy and later Opdivo, but has come under pressure as Merck & Co.'s rival treatment Keytruda moved ahead...
Bristol-Myers Squibb said on Thursday it would buy Celgene Corp. for about $74 billion, creating a major pharma company with several blockbuster cancer drugs as competition in the immunotherapy space heats up. Bristol-Myers pioneered immunotherapy with its Yervoy and later Opdivo, but has come under pressure as Merck & Co.'s rival treatment Keytruda moved ahead...
Share this Article
Recommended